Strongbridge Biopharma Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Strongbridge Biopharma stock.
View analyst ratings for Strongbridge Biopharma or view top-rated stocks.

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Strongbridge Biopharma saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,880,000 shares, an increase of 19.7% from the May 13th total of 1,570,000 shares. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.6% of the shares of the stock are short sold.
View Strongbridge Biopharma's Short Interest.

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Strongbridge Biopharma.

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Tuesday, May, 11th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $8.38 million during the quarter, compared to the consensus estimate of $8.22 million. Strongbridge Biopharma had a negative net margin of 136.23% and a negative trailing twelve-month return on equity of 72.48%.
View Strongbridge Biopharma's earnings history.

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 25.0% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19.

Strongbridge Biopharma updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $34 million-36 million, compared to the consensus revenue estimate of $36.32 million.

4 analysts have issued 1-year price targets for Strongbridge Biopharma's stock. Their forecasts range from $3.25 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $6.08 in the next twelve months. This suggests a possible upside of 109.8% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Strongbridge Biopharma include Silence Therapeutics (SLN), Sesen Bio (SESN), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Cara Therapeutics (CARA), Chimerix (CMRX), Ardelyx (ARDX), Rigel Pharmaceuticals (RIGL), Clene (CLNN), Calliditas Therapeutics AB (publ) (CALT), Esperion Therapeutics (ESPR), Bicycle Therapeutics (BCYC) and Evolus (EOLS).
View all of SBBP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (3.45%), BlackRock Inc. (3.25%), Orbimed Advisors LLC (2.58%), Renaissance Technologies LLC (2.29%), Ikarian Capital LLC (1.72%) and Geode Capital Management LLC (1.07%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ikarian Capital LLC, Renaissance Technologies LLC, Ameriprise Financial Inc., Bank of Montreal Can, Russell Investments Group Ltd., Northern Trust Corp, and First Quadrant L P CA.
View insider buying and selling activity for Strongbridge Biopharma or view top insider-selling stocks.

SBBP stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Worth Venture Partners LLC, BlackRock Inc., Dimensional Fund Advisors LP, Acadian Asset Management LLC, Cubist Systematic Strategies LLC, and Algert Global LLC. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma or or view top insider-buying stocks.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SBBP stock can currently be purchased for approximately $2.90.

Strongbridge Biopharma has a market capitalization of $196.01 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45,080,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

Strongbridge Biopharma employs 72 workers across the globe.

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]